Novartis AG (NYSE:NVS) Shares Bought by Oxbow Advisors LLC

Oxbow Advisors LLC raised its position in Novartis AG (NYSE:NVS) by 5.8% during the 4th quarter, HoldingsChannel.com reports. The firm owned 26,882 shares of the company’s stock after acquiring an additional 1,480 shares during the period. Oxbow Advisors LLC’s holdings in Novartis were worth $2,616,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Legacy Investment Solutions LLC acquired a new position in Novartis in the 3rd quarter valued at about $28,000. Human Investing LLC acquired a new position in shares of Novartis in the 4th quarter worth approximately $25,000. Union Bancaire Privee UBP SA acquired a new position in shares of Novartis in the 4th quarter worth approximately $27,000. Fortitude Family Office LLC lifted its holdings in shares of Novartis by 503.8% in the 3rd quarter. Fortitude Family Office LLC now owns 320 shares of the company’s stock worth $37,000 after acquiring an additional 267 shares during the last quarter. Finally, Kestra Investment Management LLC acquired a new position in shares of Novartis in the 4th quarter worth approximately $47,000. 13.12% of the stock is currently owned by institutional investors and hedge funds.

Novartis Price Performance

Shares of NVS opened at $109.42 on Friday. Novartis AG has a fifty-two week low of $92.35 and a fifty-two week high of $120.92. The firm’s 50 day moving average price is $101.24 and its 200 day moving average price is $108.15. The company has a market cap of $223.65 billion, a P/E ratio of 18.61, a PEG ratio of 1.70 and a beta of 0.58. The company has a quick ratio of 0.84, a current ratio of 1.04 and a debt-to-equity ratio of 0.48.

Novartis (NYSE:NVS) last announced its earnings results on Friday, January 31st. The company reported $1.98 earnings per share for the quarter, topping the consensus estimate of $1.80 by $0.18. Novartis had a net margin of 23.56% and a return on equity of 37.24%. On average, research analysts forecast that Novartis AG will post 8.45 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. HSBC lowered shares of Novartis from a “hold” rating to a “reduce” rating in a report on Wednesday, December 4th. UBS Group restated a “neutral” rating on shares of Novartis in a report on Thursday, February 13th. Morgan Stanley assumed coverage on shares of Novartis in a report on Wednesday, February 12th. They issued an “underweight” rating on the stock. Erste Group Bank restated a “hold” rating on shares of Novartis in a report on Tuesday, November 19th. Finally, StockNews.com upgraded shares of Novartis from a “buy” rating to a “strong-buy” rating in a report on Saturday, February 8th. Three equities research analysts have rated the stock with a sell rating, six have issued a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $123.38.

About Novartis

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.